Answers are grounded in this paper and cite their sources.
Perspective analysis demonstrates the potential of artificial intelligence to optimize clinical trials, highlighting a current lack of quantitative evidence supporting its impact.
Clinical trials remain the cornerstone of evidence-based medicine, yet they are frequently protracted and costly. More often than commonly thought, clinical trials are also uninformative.1 Artificial intelligence (AI) could offer an unprecedented opportunity to streamline the clinical trial lifecycle—from design to reporting—and improve the informativeness of the generated results.2 However, the amount of quantitative evidence showing the impact of AI in the context of clinical trials is scarce.
No takes yet. Share an insight, caveat, or question.
Mateen et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: